ImmuCell Corporation

What they do

The company was founded in 1982 and has been SEC-registered since 1987. It develops, manufactures and commercializes products intended to improve the survivability, health and long-term performance of neonatal dairy and beef calves. Its principal commercial line is First Defense, sold through distribution, and it recently discontinued the Re-Tain development program and is repurposing that facility and equipment for First Defense production.

Revenue drivers

• First Defense product line — The core commercial franchise of scour-prevention biologics for calves; management said U.S. calf share for scour biologics reached 19% in Q2 2026, and the line is seasonal with higher sales expected in the first calendar quarter.
• Tri-Shield — Identified by management as the primary growth driver at the producer level in Q2 2026.
• Dual-Force — Had higher sales to distribution in Q2 2026, which management characterized as normal stocking activity rather than end-demand growth.
• Functional Feed line — A smaller product line that management said continued to gain traction in Q2 2026.

Recent performance

Q2 2026 product sales rose 11.5% to $7.2 million from $6.4 million in Q2 2025, and net income was $1.8 million, or $0.20 per diluted share. Gross margin fell to 33.9% from 43.7%, which management attributed to low manufacturing volumes, scrap from a purchased-material quality issue, and costs shifted from the former Re-Tain program. Q2 2026 results included a one-time $2 million legal settlement from the former Re-Tain contract manufacturer, recorded as a reduction of operating expenses. Adjusted EBITDA was $2.7 million versus $1.4 million a year earlier. Distributor out-the-door volume growth accelerated to 28% in Q2 2026 from 21% in Q1 2026.

Strategy

The company is converting the former Re-Tain facilities and most related equipment to expand First Defense production. Phase one adds a new freeze dryer and renovates the Re-Tain facility, expected to take about 12 months and cost approximately $3.5 million, with completion targeted for the first half of 2027. Phase two repurposes Re-Tain equipment and adds equipment and automation for colostrum liquid processing, expected to take an additional six months and cost approximately $4.5 million. Management says it intends to fund both phases with cash on hand and cash from operations, and expects to roughly triple capacity over the next 18 months while prioritizing product cost improvements and colostrum sourcing.

Risks

• Gross margin compression — Gross margin fell to 33.9% in Q2 2026 from 43.7% a year earlier on lower manufacturing volumes, purchased-material scrap and Re-Tain cost absorption.
• Manufacturing capacity execution — The two capacity expansion phases require roughly $8 million in total investment and roughly 18 months, and depend on converting a facility previously used for a discontinued program.
• Sales seasonality and weather — First Defense sales are seasonal and concentrated in the first quarter beef calving season, and warm dry weather can reduce producers' perceived need for disease prevention products.
• Distributor stocking versus end demand — Q2 2025 revenue was inflated by distributor restocking after backorders, and Q2 2026 Dual-Force sales rose partly on normal stocking activity rather than producer-level demand.

Outlook

Management expects the first capacity expansion phase, about $3.5 million for freeze-drying capacity, to be completed in the first half of 2027, with the second phase, about $4.5 million for colostrum liquid processing, taking roughly six additional months. The company says it intends to fund these expansions with cash on hand and cash from operations and expects to triple capacity over the next 18 months. It also says it has made process changes to increase manufacturing yields in future quarters and is prioritizing product cost improvements.